Trial
NCT01199731
Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection
Phase IITERMINATEDSAFETYConfidence: HIGH
Sponsor
ViiV Healthcare
Collaborators
GlaxoSmithKline
Condition
Infection, Human Immunodeficiency Virus
Intervention
GSK2248761 100 mg once daily
Why stopped
The study was stopped due to safety concerns
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-11-17